Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Protagonist Therapeutics's Debt-to-EBITDA or its related term are showing as below:
PTGX'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.22 Med: -0.05 Max: 0.15
Current: 0.15
During the past 12 years, the highest Debt-to-EBITDA Ratio of Protagonist Therapeutics was 0.15. The lowest was -0.22. And the median was -0.05.
PTGX's Debt-to-EBITDA is ranked better than 79.19% of 298
companies
in the Biotechnology industry
Industry Median: 1.185
vs PTGX: 0.15
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Protagonist Therapeutics Debt-to-EBITDA Related Terms
Protagonist Therapeutics Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PTGX vs CRNX, SYRE, TGTX: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Protagonist Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Protagonist Therapeutics Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Protagonist Therapeutics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Protagonist Therapeutics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Protagonist Therapeutics (PTGX) has a Debt-to-EBITDA of 0.01 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Protagonist Therapeutics. According to the industry distribution chart, Protagonist Therapeutics ranks #62 out of 298 companies in the Biotechnology industry, placing it in the top 20.8%.
Is Protagonist Therapeutics' Debt-to-EBITDA too high?
Protagonist Therapeutics' current Debt-to-EBITDA is 0.01. The Biotechnology industry median Debt-to-EBITDA is 1.19. Protagonist Therapeutics' value of 0.01 is 99.2% below this industry median. Based on the distribution chart, Protagonist Therapeutics ranks #62 out of 298 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Protagonist Therapeutics has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Protagonist Therapeutics' Debt-to-EBITDA compare to CRNX and SYRE?
According to the Biotechnology industry distribution chart, Protagonist Therapeutics ranks #62 out of 298 companies for Debt-to-EBITDA. This places Protagonist Therapeutics in the top 21% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.19. Protagonist Therapeutics' value of 0.01 is 99.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.19, based on 298 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Protagonist Therapeutics's current Debt-to-EBITDA of 0.01 is 99.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Protagonist Therapeutics. For the Biotechnology industry, the median Debt-to-EBITDA is 1.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Protagonist Therapeutics's current Debt-to-EBITDA is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protagonist Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Protagonist Therapeutics (PTGX) is currently considered Significantly Overvalued. The stock's GF Value™ is $87.41, compared to a current price of $155.17 — trading 77.5% above its estimated fair value. The current Debt-to-EBITDA is 0.01 and 99.2% below the Biotechnology industry median of 1.19. Protagonist Therapeutics' overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Protagonist Therapeutics (PTGX), the current Debt-to-EBITDA is 0.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Protagonist Therapeutics (PTGX) Overvalued in 2026?
Based on GuruFocus' analysis, Protagonist Therapeutics stock appears to be overvalued.
The current stock price of $155.17 is trading 77.5% above its estimated GF Value™ of $87.41.
GuruFocus considers Protagonist Therapeutics to be Significantly Overvalued.
Key valuation signals for PTGX:
Debt-to-EBITDA: 0.01
GF Value™: $87.41 vs. price of $155.17 (77.5% above fair value)
Industry Position: 99.2% below the Biotechnology median (#62 of 298)
No single metric tells the full story. See the PTGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
47GF Score
Get the complete analysis for PTGX
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTGX has been successfully added to your 
